drugset
drugset / Trial / NCT02670330

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

NCT02670330 ↗

Phase 3 Terminated 152 enrolled Scioderm, Inc. Amicus Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).

Timeline

Start
2015-06-09
Primary completion
2018-09-03
Completion
2018-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject allantoin Small molecule 6 % Topical

Indications

epidermolysis bullosa